
Digi.Bio is a biotechnology company that accelerates the development of programmable cells using lab-on-a-chip technology and artificial intelligence. Their Desktop Biofoundry and cloud-enabled software automate repetitive lab workflows, providing fine-grained experimental control. They target pharmaceutical, diagnostics, and industrial biotech companies for co-development and licensing opportunities, positioning themselves as a key player in workflow automation and genetic circuit building.

Digi.Bio is a biotechnology company that accelerates the development of programmable cells using lab-on-a-chip technology and artificial intelligence. Their Desktop Biofoundry and cloud-enabled software automate repetitive lab workflows, providing fine-grained experimental control. They target pharmaceutical, diagnostics, and industrial biotech companies for co-development and licensing opportunities, positioning themselves as a key player in workflow automation and genetic circuit building.
Founded: 2017
Headquarters: Amsterdam, Netherlands (lab in Leiden)
Product: AI-driven lab-on-a-chip platform and automated digital microfluidics
Customers / Targets: Pharmaceutical, diagnostics, and industrial biotech companies (co-development & licensing)
Employees (approx.): 9
Workflow automation and high-content single-cell profiling for biotech and cell therapy development.
2017
Biotechnology
Most recent disclosed funding event listed as a convertible note dated Oct 1, 2021.
Public profiles list multiple early-stage rounds including pre-seed, seed, and non-equity assistance/grant entries.
“SOSV (HAX), Innovatiefonds Noord-Holland, MassChallenge Switzerland, ACE Incubator, plus program/grant support (SBIR/Eurostars) listed on profiles”